Regulation of Gene Expression in Hepatic Cells by the Mammalian Target of Rapamycin (mTOR) by Jimenez, Rosa H. et al.
Regulation of Gene Expression in Hepatic Cells by the
Mammalian Target of Rapamycin (mTOR)
Rosa H. Jimenez
1, Ju-Seog Lee
2, Mirko Francesconi
3, Gastone Castellani
3, Nicola Neretti
4,5, Jennifer A.
Sanders
1, John Sedivy
5, Philip A. Gruppuso
1*
1Department of Pediatrics, Rhode Island Hospital and Brown University, Providence, Rhode Island, United States of America, 2Molecular Therapeutics, University of Texas
MD Anderson Cancer Center, Houston, Texas, United States of America, 3Interdepartmental Center ‘‘L. Galvani’’, Bologna University, Bologna, Italy, 4Institute for Brain
and Neural Systems, Brown University, Providence, Rhode Island, United States of America, 5Department of Molecular Biology, Cell Biology and Biochemistry and Center
for Genomics and Proteomics, Brown University, Providence, Rhode Island, United States of America
Abstract
Background: We investigated mTOR regulation of gene expression by studying rapamycin effect in two hepatic cell lines,
the non-tumorigenic WB-F344 cells and the tumorigenic WB311 cells. The latter are resistant to the growth inhibitory effects
of rapamycin, thus providing us with an opportunity to study the gene expression effects of rapamycin without
confounding effects on cell proliferation.
Methodology/Principal Findings: The hepatic cells were exposed to rapamycin for 24 hr. Microarray analysis on total RNA
preparations identified genes that were affected by rapamycin in both cell lines and, therefore, modulated independent of
growth arrest. Further studies showed that the promoter regions of these genes included E-box-containing transcription
factor binding sites at higher than expected rates. Based on this, we tested the hypothesis that c-Myc is involved in
regulation of gene expression by mTOR by comparing genes altered by rapamycin in the hepatic cells and by c-Myc
induction in fibroblasts engineered to express c-myc in an inducible manner. Results showed enrichment for c-Myc targets
among rapamycin sensitive genes in both hepatic cell lines. However, microarray analyses on wild type and c-myc null
fibroblasts showed similar rapamycin effect, with the set of rapamycin-sensitive genes being enriched for c-Myc targets in
both cases.
Conclusions/Significance: There is considerable overlap in the regulation of gene expression by mTOR and c-Myc. However,
regulation of gene expression through mTOR is c-Myc-independent and cannot be attributed to the involvement of specific
transcription factors regulated by the rapamycin-sensitive mTOR Complex 1.
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Introduction
The mammalian Target of Rapamycin (mTOR) is a central
regulator of many biological processes that are essential for cell
growth, including cell cycle progression, protein translation,
ribosomal biogenesis, autophagy and metabolism [1,2]. In
addition, alterations in mTOR signaling have been associated
with the pathophysiology of cancer [3,4] and aging [5]. Among the
effects of mTOR signaling, regulation of gene expression and
transcription is well characterized for several specific genes,
including DNA polymerase I (Pol I), Insulin Growth Factor II
(IGF II), ribosomal DNA [6–8] and regulators of mitochondrial
oxidative function [9]. However, general effects on gene expression
have not been well characterized, and the mechanisms by which
mTOR signaling affects the expression of a broad array of genes
are less well defined than is the case for its other biological effects.
mTOR interacts with a number of protein partners, including
raptor (regulatory associated protein of TOR) and rictor
(rapamycin-insensitive companion of TOR), which form com-
plexes with mTOR termed mTORC1 and mTORC2, respec-
tively [10]. mTORC1-mediated signaling events are sensitive to
the macrolytic lactone, rapamycin, while events downstream from
mTORC2 are, in general, rapamycin insensitive [11].
The role of TOR in the regulation of transcription has been best
characterized in yeast [12] where the nuclear localization and the
activity of several nutrient and stress-responsive transcription
factors are regulated by TORC1-dependent phosphorylation [13].
Yeast TOR signals to a number of specific effectors including
Tap42, Mks1p, Ure2p, Gln3p, Npr1, Tip41, and Gat1p, all of
which can elicit changes in the expression levels of enzymes
involved in metabolic pathways [14,15]. As a nutrient-sensing
kinase, TOR signaling regulates the subcellular localization of the
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is involved in the regulation of nutrient-sensitive, TORC1-
controlled transcription pathways in yeast and mammals [16].
Examples of rapamycin-sensitive mTORC1 signaling to
transcriptional regulators have been identified in eukaryotes.
mTOR phosphorylates the signal transducers and activators of
transcription 1 and 3 (STAT1 and STAT3) and, as a result,
induces the transcription of the nuclear receptor peroxisome
proliferator-activated receptors-gamma (PPARc) [13]. In addition,
mTOR signaling occupies a central role in the global regulation of
ribosomal RNA synthesis through the TIF-IA transcription factor
[17]. Finally, mTOR-mediated regulation of mitochondrial
oxidative function occurs through regulation of a transcription
factor termed YY1 [9].
We have characterized the effects of rapamycin on gene
expression in two related rat liver epithelial cell lines [18]. The
slow growing, non-tumorigenic WB-F344 [19] cell line is sensitive
to the anti-proliferative effects of rapamycin while the faster
growing, tumorigenic WB311 cell line, spontaneously derived
from the WB-F344 cell line [20], is not. We used microarray
analysis to characterize the effects of rapamycin on gene
expression in these two cell lines. The results identified 106 genes
whose expression was altered in response to rapamycin in both cell
lines and, therefore, affected independent of rapamycin-induced
growth arrest. We hypothesized that this set of genes would be
regulated through effects on specific transcription factors and,
therefore, be suitable for further study aimed at identifying
transcriptional control mechanisms downstream from mTORC1.
Methods
Cell Culture
Culture conditions for the WB-F344 [19] and WB311 [20] cell
lines have been previously described. Conditions for maintaining
the TGR-1 (c-myc
+/+) and HO15.19 (c-myc
2/2) cells have been
published as well [21]. All cell lines were grown at 37uC with 5.0%
CO2 and plated at densities providing for approximately 60 to 80
percent confluence at the time of each experiment. After plating,
cells were allowed to recover for at least 18 hr before exposure to
rapamycin.
Identification of Predicted Transcription Factor Binding
Sites
The TOUCAN 2 web based program [22,23], which integrates
several data and algorithmic resources including TRANSFAC,
JASPAR, Ensembl, MotifScanner and MotifSearcher, was used to
identify overrepresented transcription factor binding sites in the
proximal promoters or the distal non-coding sequence in defined
sets of co-regulated or co-expressed genes. For the retrieval of
promoter sequences from the Ensemble database, the following
settings were used: Get_Seq from Ensembl/Biomart, comma
separated, rat species, AFFY_Rat230_2 chip, 59Upstreatm Exon
1, 1,000 base pairs (bp) upstream, 200 bp downstream, add to
current list, Rev Compl automatically. To search for transcription
factor binding sites, MotifScanner was used with the following
settings: motif Position Weight Matrix (PWM) scoring, Motif
Scanner, P2: TRANSFAC 7.0, P3: Prior 0.1, P4: background
model (mouse DBTSS promoters [3]), stand integer 1. Note that
the background model for the rat was not available in the
TOUCAN2 program. Therefore, we used mouse as the
background model.
The TOUCAN2 analysis was followed by statistical analysis to
identify overrepresented transcription factor binding sites. The
following parameters were used: Expected Frequencies file:
epd_mus_musculus_prior 0.1.freq. Note that the expected fre-
quencies file was not available for the rat, so the file for mouse was
used. The prior that was used was the same as for the
MotifScanner run. The expected frequencies file, located on the
TOUCAN FTP-site, is based on the Eukaryotic Promoter
Database (http://www.epd.isb.ch/seq_download.html).
Analysis of Myc Family Gene Expression
WB-F344 cells were plated in 100 mm plates and allowed to
attach overnight. Vehicle (DMSO) or 50 nM rapamycin was
added for 6 or 24 hr. Total RNA was prepared from triplicate
plates using TRIzol reagent. RNA integrity was determined using
an Agilent Bioanalyzer. RNase protection assays were performed
using the RPA III kit (Ambion; Austin, TX) and
32P-labeled
probes generated from the RiboQuant mMyc multiprobe template
(BD Biosciences; San Jose, CA) using the T7 MAXIscript kit
(Ambion).
RNA Isolation and Microarray Hybridization for the
HOMyc-ER12 Fibroblasts
The experimental conditions for expression profiling of c-Myc
target genes induced by 4-hydroxytamoxifen (OHT) in HOMy-
cER12 fibroblasts have been described previously [24]. Genes
were clustered according to their expression pattern over time.
Unsupervised hierarchical clustering analysis with correlation-
based metrics resulted in 9 clusters. Cluster 1 (1,712 probesets)
consists of rapidly downregulated c-Myc target genes that remain
downregulated for 24 hr. Cluster 2 (1,643 probesets) represents
rapidly upregulated genes that remain upregulated. Cluster 3 (616
probesets) contains genes that are quickly downregulated after
exposure to OHT then return towards the baseline but remain
downregulated at 24 hr. Cluster 4 (178 probesets) represents genes
that are quickly upregulated from 1 to 6 hr then fall to baseline.
Cluster 5 genes (30 probesets) are rapidly downregulated by OHT
from 1 to 6 hr then return towards the baseline by 24 hr. Clusters
6 through 9 had fewer than 5 genes each, so they were not
included in the present analyses.
Identification of c-Myc Targets among Rapamycin
Responsive Genes
The dataset of genes that were differentially expressed in
response to rapamycin in the WB-F344 and WB311 hepatic cells
and the c-Myc target gene dataset in HOMycER12 fibroblasts
were compared to search for c-Myc targets in hepatic cells and the
fibroblast cell lines. To accomplish this, the ID Converter
Database (http://idconverter.bioinfo.cnio.es/) was used to obtain
the Ensembl Gene ID and Entrez ID for the list of rapamycin-
sensitive genes in the WB-F344 and WB311 hepatic cells and the
c-Myc target genes in HOMycER12 fibroblasts. Genes that
contained more than one probe ID in the list of differentially
expressed genes affected by rapamycin in the WB-F344 and
WB311 cells were counted only one time when compared to the
existing list of c-Myc targets to avoid overestimating the
intersection of the two groups. Therefore, while the total number
of Affymetrix probe ID for genes affected by rapamycin in the
WB-F344 cells was 2,034, only 1,927 were used for this analysis.
While the total number of Affymetrix probe IDs affected by
rapamycin in the WB311 cells was 1,236, only 1,130 were used for
this analysis.
In addition to the above analysis, the dataset of rapamycin-
sensitive genes in the WB-F344 and WB311 cells was aligned with
341 confirmed NFkB target genes previously identified in multiple
human cell lines (http://people.bu.edu/gilmore/nf-kb/target/
Gene Expression and mTOR
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second analysis using a gene expression regulating system other
than c-Myc to assess the specificity of our findings.
E-Box Content and Distribution for Rapamycin
Responsive Genes in Hepatic Cells
The Affymetrix gene features affected by rapamycin in the WB-
F344 and WB311 cells were subjected to further analysis.
Promoter regions of annotated genes extending from 3,000 bp
upstream to 500 bp downstream of the transcription start sites
were extracted from our datasets. The search for E-boxes was
restricted to a perfect match with the canonical E-box CACGTG
in the promoter sequences [25]. Statistical significance of the
results was assessed using a Fisher exact test.
Profiling of Rapamycin Effect on Gene Expression in Rat
Fibroblasts
TGR-1 cells (c-myc
+/+) and HO15.19 cells (c-myc
2/2) were
plated in 100 mm plates and allowed to attach overnight. Vehicle
(DMSO) or 50 nM rapamycin was added for 24 hr. Total RNA
was prepared from three independent biological replicates using
TRIzol reagent. RNA processing, hybridization and data analysis
were carried out at the W. M. KECK Foundation Biotechnology
Resources Laboratory at Yale University (New Haven, CT). Gene
expression was analyzed using the Illumina RatRef-12 Expression
BeadChips and the fluorescence signals were normalized using
quantile normalization implemented in BeadStudio (Illumina Inc.,
San Diego, CA). Illumina data analysis was performed using
PartekH software, version 6.3 (Partek Inc., St. Louis, MO). For
gene expression comparisons, genes whose change had a level of
significance of P.0.01 or fold change less than 1.2-fold were
excluded from further analyses. A two-sample t-test using a P-
value cutoff of 0.05 with multiple test correction (Benjamini and
Hochberg false discovery rate) was applied for each gene to
determine if the gene was differentially expressed in the pairwise
comparisons of triplicate analyses [26].
Pathway Analysis
Significantly altered genes from each comparison were mapped
to the Kyoto Encyclopedia of Genes and Genomes (KEGG)
biopathway database (http://www.genome.ad.jp/kegg/pathway.
html). For the Fisher exact test, P-values were employed to
determine the enriched gene ontology categories and the
overrepresented pathways. The list of differentially expressed
genes in each cell line was used for the network reconstruction of
pathway analysis, which was performed as described elsewhere
[27].
Data Access and Analysis
The microarray studies described in this paper have been
deposited in the NCI’s Gene Expression Omnibus (GEO; [28])
and comply with the Minimal Information About a Microarray
Experiment (MIAME) standard developed by the MGED Society
(http://www.mged.org/Workgroups/MIAME/miame.html). Da-
ta derived from the hepatic cell lines may be accessed through the
GEO SuperSeries accession number GSE17677 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17677). Data de-
rived from the rat fibroblast cell lines may be accessed using
accession number GSE18845 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE18845).
Chi square analysis was used to determine whether observed
frequencies differed from the expected frequencies in the various
analyses.
Results
Clustering Analysis
We previously characterized the gene expression response to
rapamycin for the WB-F344 and WB311 hepatic cell lines [18].
Cells were exposed to DMSO vehicle or rapamycin (50 nM) for
24 hr prior to preparation of RNA for microarray analysis. A total
of 2,346 gene features showed significant differences across the
four experimental groups (2 cell lines, each without or with
rapamycin). Hierarchical clustering (Figure 1A) showed that the
vehicle control and rapamycin groups segregated for the
rapamycin-sensitive WB-F344 cells but not for the rapamycin-
resistant WB311 cells. We proceeded to perform a cross-
comparison analysis of expression patterns in these two cell lines.
Gene expression ratios were median-centered across the 6
analyses of each cell line. A cross comparison of expression
patterns (Figure 1A) showed that 791 gene features were
exclusively altered in WB-F344 cells after rapamycin treatment
while 484 gene features were exclusively altered in the WB311
cells. Of particular interest were 106 gene features that were
affected by rapamycin in both cell lines. Examination of the 106
gene features (Figure 1B) showed that the expression of 26 of the
genes was affected in opposite directions in the WB-F344 and
WB311 cells. The 80 gene features that were co-regulated in
response to rapamycin in the two cell lines (Table S1) were
selected for further study. Thirty-three of these genes were
upregulated in both cell lines while 47 were downregulated.
Identification of Overrepresented Transcription Factor
Binding Sites in Rapamycin-Regulated Genes in Hepatic
Cells
Genes co-regulated by rapamycin in the two cell lines are
necessarily regulated independent of growth arrest since the
WB311 cells are rapamycin resistant. Our initial hypothesis was
that these genes share a common transcriptional control
mechanism and, therefore, specific transcription factor binding
sites. Of the 80 co-regulated gene features, only 61 had Ensemble
IDs and could therefore be recognized by TOUCAN 2. Analysis
of the promoter regions of these genes revealed five high-scoring
transcription factor matrices that were overrepresented in the
designated set of promoters. All five represented binding sites with
E-boxes (CACGTG) that corresponded to the consensus sites for
the transcription factors Max, MycMax_01, MycMax_02, Myc-
Max_03, and Arnt (Table 1). Nineteen of the 61 genes contained
binding sites for these transcription factors (Table 2). Some of
these genes contained more than one E-box-containing transcrip-
tion factor binding in its promoter region. In addition, the binding
site that correlated with a specific transcription factor differed in
some cases. For example, the transcription factor M00119-
V$Max_01 was predicted to bind the motifs TAATCACGT-
GATTG and CAATCACGTGATTA in the promoter of the
Eif4b gene while it was predicted to bind the motifs GCAA-
CACGTGACTC and GAGTCACGTGTTGC in the promoter
of the Ecm1 gene.
Enrichment of c-Myc Targets in Rapamycin-Modulated
Genes in the WB-F344 and WB311 Hepatic Cell Lines
Based on the overrepresentation of E-box-containing transcrip-
tion factor binding sites among rapamycin-regulated genes, we
hypothesized that c-Myc plays a role in the regulation of gene
expression by mTOR. Using the WB-F344 cells, we examined the
effect of mTOR on members of the Myc signaling network using a
multiplex RNase protection assay [29]. Results (Figure 2) showed
Gene Expression and mTOR
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state expression of Max and Mad 4. However, the effect was not as
marked as the effect on the two genes intended for use as internal
standards, ribosomal protein L32 and GAPDH. Of note, members
of the Myc family were not affected. At 24 hr, there were no
persistent effects on any of the components of the Myc signaling
network, L32 or GAPDH. The upregulation of c-myc at the longer
time point did not reach statistical significance.
We next tested the hypothesis that c-Myc targets would be
enriched among the set of mTORC1 targets in both the WB-F344
and WB311 cells. We compared the set of rapamycin-responsive
genes in the two hepatic cell lines with a set of c-Myc targets
identified in HOMycER12 fibroblasts during c-myc induction for
up to 24 hr. Results (Figure 3, upper panel) showed that 699 of the
1,927 rapamycin-responsive genes identified in the WB-F344 cells
were c-Myc targets. This was significantly greater than the
expected number of 377 (P,0.000001). Examination of the
distribution of genes among the clusters representing various
temporal responses to c-myc induction revealed a higher than
expected proportion of genes contained in clusters 1
(P,0.000001), 2 (P,0.000001) and 3 (P,0.01).
Figure 1. Microarray analysis of the effect of rapamycin on gene expression in hepatic cells. WB-F344 and WB311 cells were exposed to
DMSO vehicle or rapamycin (50 nM) for 24 hr. Total RNA was prepared and processed for microarray analysis. Panel A shows a clustering analysis and
heat map for the expression of all gene features that showed a significant change in response to rapamycin across the four experimental conditions
(two cell lines, each plus and minus rapamycin). The accompanying Venn diagram shows the gene features affected in one cell line, the other or in
both. Panel B shows a magnification of the gene expression pattern of the 106 gene features in the middle box of Panel A, representing those that
were affected by rapamycin in both cell lines. The blue boxes at the top and in the middle of the heat map represent gene features that were
regulated in opposite directions in the WB-F344 and WB311 cells after treatment with rapamycin. The gene features that are not included in the blue
boxes represent genes that were co-regulated in the two cell lines.
doi:10.1371/journal.pone.0009084.g001
Table 1. Overrepresented transcription factor binding sites
identified among rapamycin sensitive genes in the WB-F344
and the WB311 hepatic cell lines.
Feature Name n * Probability
{ Significance
{
M00119-V$MAX_01 20 1.64E-07 4.363
M00118-V$MYCMAX_01 13 2.66E-04 1.154
M00615-V$MYCMAX_03 20 4.86E-04 0.892
M00236-V$ARNT_01 17 0.001 0.562
M00123-V$MYCMAX_02 18 0.003 0.108
*n represents the number of times a feature (transcription factor) appeared
among the set of gene promoters loaded into the TOUCAN2 program.
{Probability represents the P-value associated with the analysis; p-values less
than 0.05 were considered significant and these binding sites were considered
to be overrepresented.
{Significance is shown here because multiple features (more than one
promoter) were interrogated. Positive significance values indicate statistically
significant results.
doi:10.1371/journal.pone.0009084.t001
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factor binding sites with integral E-boxes.*
Affimetrix Rapa Effect
Rapa
Effect Transcription Factor
Identifier Gene Symbol WB-F344 WB311
Binding
Site Identifier
Transcription Factor
Binding Site Sequence
1372124_at Eif4b_predicted || eukaryotic
translation initiation factor 4B
1.42 1.52 M00118-V$MYCMAX_01 TATAATCACGTGATTG
M00119- V$MAX_01 TAATCACGTGATTG and CAATCACGTGATTA
M00123-V$MYCMAX_02 ATAATCACGTGATT and AATCACGTGATT and
AATCACGTGATT
M00236-V$ARNT_01 ATAATCACGTGATTGC
M00615-V$MYCMAX_03 CTATAATCACGTGATTGCCT and
AGGCAATCACGTGATTATAG
1385027_at Transcribed locus 1.60 -- M00118-V$MYCMAX_01 CATCCACGTGCCTG
1379904_at No Designation 1.39 1.40 M00123-V$MYCMAX_02 CAGCACGCGTGT
M00236-V$ARNT_01 CGACTCACGTGACGCT
M00615-V$MYCMAX_03 CTCGACTCACGTGACGCTAC and
GTAGCGTCACGTGAGTCGAG
1388698_at Ecm1 || extracellular matrix protein 1 2.25 1.44 M00119- V$MAX_01 GCAACACGTGACTC and GAGTCACGTGTTGC
M00123-V$MYCMAX_02 CCGCACGTGTCT and CAACACGTGACT
M00236-V$ARNT_01 AGAGTCACGTGTTGCC
M00615-V$MYCMAX_03 CCGGCAACACGTGACTCTAG and
CTAGAGTCACGTGTTGCCGG
1387294_at Sh3bp5 || SH3-domain binding
protein 5 (BTK-associated)
1.75 1.28 M00236-V$ARNT_01 GGGACCACGTGAGGTC
1368453_at Fads2 || fatty acid desaturase 2 -1.64 -1.36 M00123-V$MYCMAX_02 CACCACATGGGA
1385426_at RGD1305326_predicted || similar
to hypothetical protein FLJ20647
-1.45 -1.30 M00118-V$MYCMAX_01 AAACCACGTGGTCA and TGACCACGTGGTTT and
CGACCACCTGCAGG
M00119- V$MAX_01 AAACCACGTGGTCA AND TGACCACGTGGTTT
M00123-V$MYCMAX_02 GGAAAACCACGTGGTCAATG and
CATTGACCACGTGGTTTTCC
M00615-V$MYCMAX_03 CGAAACCACCGTGGTCAAT and
CATTGACCACGTGGTTTCC
1386907_at Eno3 || enolase 3, beta -2.54 -1.33 M00118-V$MYCMAX_01 TGTACACGTGCTCG and CGAGCACGTGTACA
M00119- V$MAX_01 TGTACACGTGCTCG
M00123-V$MYCMAX_02 GAGCACGTGTAC
M00236-V$ARNT_01 ATGTACACGTGCTCGA
M00615-V$MYCMAX_03 ACATGTACACGTGCTCGACT
1389228_at Similar to RIKEN cDNA
2010309E21 (predicted)
21.53 21.26 M00118-V$MYCMAX_01 AACACACGTGGTCG and CGACCACGTGTGTT
M00119- V$MAX_01 CGACCACGTGTGTT and AACACACGTGGTCG
M00123-V$MYCMAX_02 GACCACGTGTGT
M00236-V$ARNT_01 AAACACACGTGGTCGC
M00615-V$MYCMAX_03 TGAAACACACGTGGTCGCTG
1371332_at Histone 1, H4a (predicted) 21.41 21.29 M00123-V$MYCMAX_02 AACCACATGATA
1367857_at Fads1 || fatty acid desaturase 1 21.55 21.52 M00119- V$MAX_01 TTGTCACGTGTTTC and GAAACACGTGACAA
M00123-V$MYCMAX_02 AAACACGTGACA
M00236-V$ARNT_01 TTTGTCACGTGTTTCC
M00615-V$MYCMAX_03 AAGGAAACACGTGACAAATT and
AATTTGTCACGTGTTTCCTT
1383434_at Transcribed locus 21.81 21.38 M00236-V$ARNT_01 TGGATAACGTGTGCGC
1368079_at Pdk1 || pyruvate dehydrogenase
kinase 1
21.52 21.41 M00118-V$MYCMAX_01 CTACCACGGTGGTGT and ACACCACGTGGTAG
M00119- V$MAX_01 CTACCACGTGGTGT and ACACCACGTGGTAG
M00123-V$MYCMAX_02 CACCACGTGGTA
Gene Expression and mTOR
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and c-Myc might induce parallel changes in gene expression and
that rapamycin effect would reflect this (Figure 3, upper panel).
For cluster 1, c-Myc targets that were rapidly and persistently
downregulated following c-myc induction in the HOMycER12
fibroblasts, there was no difference between the number of c-Myc
targets that were upregulated and downregulated in response to
rapamycin in the WB-F344 cells. For cluster 2, which represents
genes that were upregulated following c-myc induction, the
majority of c-Myc targets in this cluster (268 of 293 probesets)
were downregulated in response to rapamycin. For cluster 3 (genes
that were rapidly downregulated then moved towards baseline but
remained downregulated at 24 hr following c-myc induction), the
majority of c-Myc targets (108 of 118 probesets) were downreg-
ulated in response to rapamycin. These results indicated limited
consistency in the effects of mTORC1 inhibition and c-Myc on
the expression of c-Myc target genes.
In the WB311 cell line (Figure 3, lower panel), 342 of 1130
rapamycin-modulated genes were present in the c-Myc target
dataset. This number surpassed the expected number of 221, a
difference that was significant (P,0.000001). A significant associa-
tion between rapamycin effect and the effect of c-myc induction was
confined to clusters 1 and 3. For cluster 1, of the 178 probesets that
responded to rapamycin (versus the expected number of 111
probesets), the expression of 111 c-Myc targets was increased while
67 were repressed (P,0.000001). For cluster 3, the observed
number of c-Myc targets (44 probesets) exceeded the expected
number (37 probesets) (P,0.05). Approximately equal numbers
were upregulated and downregulated.
To assess the specificity of the relationship between c-Myc and
mTORC1 signaling, we performed a similar analysis using the set
of 341 genes that are targets of NFkB. We chose NFkB because,
like c-Myc, it is involved in the regulation of a large, diverse set of
genes involved in a spectrum of cellular processes [30]. The results
of this comparison disclosed that only 27 of the 1,927 rapamycin-
responsive genes in the WB-F344 cells were included among the
NFkB targets. This number was not significantly greater than the
expected number. A similar result was obtained for the WB311
cell line in which only 26 of the 1,130 rapamycin-responsive genes
were included in the NFkB dataset.
Affimetrix Rapa Effect
Rapa
Effect Transcription Factor
Identifier Gene Symbol WB-F344 WB311
Binding
Site Identifier
Transcription Factor
Binding Site Sequence
MOO615-V$MYCMAX_03 ATCCTACCACGTGGTGTTTC
1372132_at Cndp2_predicted || CNDP dipeptidase
2 (metallopeptidase M20 family)
21.90 21.47 M00119- V$MAX_01 GCACCACGTGTCTC and GAGACACGTGGTGC
M00123-V$MYCMAX_02 CACCACGTGTCT
M00236-V$ARNT_01 AGAGACACGTGGTGCG
M00615-V$MYCMAX_03 TCCGCACCACGTGTCTCTGC and
GCAGAGACACGTGGTGCGGA
1375964_at Psph_predicted || phosphoserine
phosphatase (predicted)
21.89 21.50 M00123-V$MYCMAX_02 TCGCACGTTGCA
1371445_at RGD1305092_predicted || similar to
ribosome-binding protein p34 - rat
21.57 21.29 M00119-V$MAX_01 GTGACACGTGCCTT
M00236-V$ARNT_01 AGTGACCGTGCCTTC
M00615-V$MYCMAX_03 CAGAAGGCACGTGTCACTCA and
TGAGTGACACGTGCCTTCTG
1377016_at RGD1310614_predicted || similar
to RIKEN cDNA 5730592L21
21.46 21.43 M00236-V$ARNT_01 GAGAGCGCGTGACGGC
1375669_at LOC293702 || similar to binding protein 21.40 21.30 M00236-V$ARNT_01 CTAGGCACGTGCACTC and GAGTGCACGTGCCTAG
1367743_at Pfkl || phosphofructokinase, liver, B-type 21.39 21.36 M00119-V$MAX_01 ATGCCACGTGGTTC and GAACCACGTGGCAT
M00118-V$MYCMAX_01 ATGCCACGTGGTTC and GAACCACGTGGCAT
M00119-V$MAX_01 ATGCCACGTGGTTC and GAACCACGTGGCAT
M00123-V$MYCMAX_02 AACCACGTGGCA and AACCACGTGGCA
M00236-V$ARNT_01 GATGCCACGTGGTTCT and AGAACCACGTGGCATC
M00236-V$ARNT_01 GATGCCACGTGGTTCT and AGAACCACGTGGCATC
M00615-V$MYCMAX_03 CCGATGCCACGTGGTTCTCC and
GGAGAACCACGTGGCATCGG
M00615-V$MYCMAX_03 CCGATGCCACGTGGTTCTCC and
GGAGAACCACGTGGCATCGG
*Of the 61 co-regulated gene features, 19 were found to have one or more than one E-box-containing transcription factor binding site. For each of these gene
features, the fold-change in response to rapamycin, the transcription factor binding site identification and the sequence within the specific gene feature
containing that site is shown. ‘‘Rapa Effect’’ denotes the fold-change in response to rapamycin for each individual gene. Note that the fold change in response to
rapamycin for 1385027_at could not be determined because two distinct normalization procedures were employed for the clustering versus the differential
expression analyses.
doi:10.1371/journal.pone.0009084.t002
Table 2. Cont.
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Rapamycin-Modulated Genes
We hypothesized that the distribution of E-boxes would differ in
the promoter regions of genes that were up-regulated versus down-
regulated in response to rapamycin. For the population of
rapamycin-responsive genes in the two hepatic cell lines, E-boxes
showed a positional bias in that most were located within a region
100 nucleotides upstream of the transcriptional start site
(Figures 4A and 4B). There was no apparent difference in the
distribution of E-boxes in the two cell lines. In addition, the
number of E-box-containing sites among promoters for rapamy-
cin-responsive genes showed similar results for the two cell lines
(Figures 4C and 4D). However, the number of promoters with two
E-boxes was higher for genes that were downregulated by
rapamycin in the WB-F344 cells compared to the genes that were
upregulated. This was not the case for the WB311 cells.
Dependence of Rapamycin Effect on c-Myc in Fibroblasts
To assess the dependence of rapamycin-induced changes in
gene expression on c-Myc, we performed studies on two rat
fibroblast cell lines, TGR-1 (c-myc
+/+) and HO15.19 (c-myc
2/2).
Preliminary studies (data not shown) confirmed that the phos-
phorylation of ribosomal protein S6 (Ser
235/236) was highly
sensitive to inhibition by rapamycin in both cell lines. Studies
using
3H-thymidine showed that both cell lines were resistant to
the growth inhibitory effects of rapamycin (data not shown) based
on the criteria that we had established using hepatic cells [18].
We hypothesized that the effect of rapamycin on gene
expression would be c-Myc-dependent and that this would be
reflected in there being fewer rapamycin-sensitive genes in the
HO15.19 fibroblasts (c-myc
2/2) than in TGR-1 cells (c-myc
+/+).
Both cell lines were exposed to DMSO vehicle or rapamycin
(50 nM) for 24 hr. Total RNA was prepared and processed for
microarray analysis. Results for the TGR-1 cells showed that 989
gene features (4.5% of the total number on the array) were affected
by rapamycin with 521 sequence tags upregulated and 463
downregulated. In the HO15.19 fibroblasts 1,140 probes (5.2% of
the total number of gene features on the array) were affected by
rapamycin (553 upregulated and 590 downregulated). The
Figure 2. The effect of rapamycin on the expression of
components of the Myc signaling network. WB-F344 cells were
treated with rapamycin for 6 hr (Panel A)o r2 4h r( Panel B). At the end of
the incubation period, total RNA was prepared from triplicate wells for
each condition. RNA (21 mg) was analyzed by multiplex RNase protection
assay. Results are expressed as the mean + 1SD. The asterisks indicate a
significant difference from the control group as determined by unpaired
t-test. The densitometry units are arbitrary and should not be used to
compare the relative expression of one gene versus another, only the
effect of rapamycin. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
doi:10.1371/journal.pone.0009084.g002
Figure 3. Enrichment of c-Myc targets among rapamycin
targets in hepatic cell lines. Microarray results identifying genes
affected by rapamycin in WB-F344 cells (Upper Panel) and WB311 cells
(Lower Panel) were compared to c-Myc targets. The latter were
identified as genes whose expression was altered in response to c-
myc induction by OHT in HOMycER12 fibroblasts. The expected
(unfilled), observed (black), upregulated (red) and downregulated
(green) c-Myc targets regulated in response to rapamycin are shown
for the temporal response clusters 1, 2 and 3 in the HOMycER12
fibroblasts and for the total population of genes affected in these cells.
*, P,0.05 versus corresponding control were determined by chi square
analysis.
doi:10.1371/journal.pone.0009084.g003
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greater than the number in the TGR-1 cells, thus refuting our
hypothesis. This conclusion was further supported by the
observation that the number of genes showing a 1.5-fold or
greater change in expression was higher in the HO15.19 cells than
in the TGR-1 cells (data not shown).
Based on the results in hepatic cell lines, we hypothesized that
the genes affected by rapamycin in the TGR-1 and HO15.19 cells
would show enrichment of c-Myc targets. Results (Figure 5)
confirmed this hypothesis in both cells lines. In the TGR-1 cells,
430 of 989 rapamycin modulated genes were in the set of c-Myc
targets, far exceeding the expected 192 genes (P,0.000001). As in
the hepatic cell lines, the number of rapamycin-sensitive c-Myc
targets identified in the two fibroblast lines in clusters 1, 2 and 3
exceeded the number expected.
The direction of regulation in response to rapamycin was
examined. For TGR-1 cells (Figure 5, upper panel) cluster 1 genes
(downregulated in response to c-myc induction), rapamycin
induced upregulation of the expression of 167 c-Myc targets while
only 29 were downregulated. Among cluster 2 genes (upregulated
in response to c-myc induction), rapamycin upregulated the
expression of 23 c-Myc targets while 159 were downregulated.
Similar results were obtained for the HO15.19 cell line (Figure 5,
lower panel).
Pathway analysis revealed that rapamycin modulated the
expression of genes involved in a number of biochemical and
metabolic pathways in both the TGR-1 and HO15.19 fibroblasts
(Table 3). These pathways included those involved in steroid,
carbohydrate and amino acid metabolism. As was the case for the
WB-F344 and WB311 hepatic cells [18], rapamycin affected the
glycolysis/gluconeogenesis pathway with phosphoglycerol kinase 1
(Pgk1) being downregulated in both cell lines. This was the only
case of a gene being regulated in a manner that determined
activity of a pathway in all four cell lines.
Pathway network reconstruction analysis was also performed in
order to identify critical genes affected by rapamycin among the
interphase of connected pathways. This analysis has already been
reported for the WB-F344 and WB311 cells [18]. It showed that
Figure 4. Distribution and number of canonical E-box elements (CACGTG) among rapamycin sensitive genes. Identification of the E-
boxes and their distribution was performed as described in the methods section. The promoter sequences spanning 23 kb upstream to +500 bases
downstream of the transcriptional start site (TSS) were used in this analysis. Distribution (frequency as a function of position relative to +1, the TSS) of
each E-box sequence is shown for WB-F344 cells (Panel A) and WB311 cells (Panel B). The distribution of the number of E-boxes along the promoters
of genes affected by rapamycin is shown for the WB-F344 cells (Panel C) and the WB311 cells (Panel D). Density (Y-axis) is a probability function
representing the normalized frequency of E-boxes. Black lines denote the total number of E-boxes detected in the database, red lines represent E-
boxes in the promoters of genes upregulated by rapamycin and blue lines represent the genes downregulated by rapamycin.
doi:10.1371/journal.pone.0009084.g004
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critical pathways in both cell lines. In the TGR-1 cells treated with
rapamycin, a number of overrepresented pathways were similarly
interconnected to these two genes (Figure 6A). Both genes were
upregulated by rapamycin in the TGR-1 cells. Neither was
identified in the pathway network reconstruction analysis for the
HO15.19 cell line (Figure 6B), perhaps consistent with the fact that
these cells lack c-Myc.
Discussion
The present studies were undertaken for the purpose of
identifying new mechanisms by which signaling via the mTOR
pathway regulates gene expression at the transcriptional level. Our
starting point was a series of studies on two hepatic cell lines, one
that is sensitive to the anti-proliferative effects of rapamycin and
one that is not. We reasoned that the set of genes whose expression
was modulated in response to rapamycin in both cell lines would
represent genes whose control was independent of growth arrest.
We further expected that examination of the promoter regions of
these genes would allow for the identification of transcription factor
binding domains for mTORC1-responsive transcription factors.
The results we obtained were unexpected. The only transcrip-
tion factor binding sites that were identified contained E-boxes, the
consensus sequence of which is CANNTG, with a palindromic
canonical sequence of CACGTG [31,32]. We interpreted this
result as indicating that rapamycin-induced inhibition of signaling
by mTORC1 might affect transcriptional control by the c-Myc
network [25]. Such a conclusion was supported by the
commonality in the biological functions of mTOR and c-Myc.
Both regulate cell growth, metabolism, gene expression, ribosome
biogenesis and protein translation [13,21,33,34].
In order to test the hypothesis that there was a functional
intersection between mTORC1 signaling and c-Myc regulation of
gene expression, we interrogated the list of rapamycin-sensitive
genes for their presence in a population of genes whose expression
was regulated in response to the induction of c-myc in rat
fibroblasts. This approach to identifying c-Myc targets involved
not just the detection of changes in expression but also a kinetic
expression profiling analysis [24]. By using this approach, we were
able to assess not just the intersection between the populations of
genes regulated by c-Myc and mTORC1, but also the upregula-
tion versus downregulation of these genes. The results of this
analysis demonstrated that c-Myc targets were indeed over-
represented among the population of rapamycin-sensitive genes.
With regard to direction of regulation, there was a modest
concordance that was consistent with co-regulation by c-Myc and
mTORC1, two positive regulators of cell growth and proliferation.
Furthermore, these observations pertained to both the rapamycin-
sensitive and rapamycin-resistant cell lines. The significance of
these observations was supported by a similar analysis using a
population of genes identified as targets for NFkB. In this case, no
relationship with mTORC1 effects was identified.
Based on the intersection between the populations of genes
regulated by mTORC1 and c-Myc, we hypothesized that c-Myc
might be a direct or indirect participant in the pathway by which
mTORC1 regulates gene expression. To test this hypothesis, we
characterized rapamycin-induced changes in gene expression in
the HO15.19 cell line. These cells were originally derived from
TGR-1 cells, which were in turn derived from the Rat-1 fibroblast
cell line [35]. HO15.19, made null for c-myc by homologous
recombination [21], are an appropriate model system for studying
the role of c-myc in a variety of cell processes. In addition, the
TGR-1 and HO15.19 cells represented a second model system in
which we were able to confirm the intersection in the regulation of
gene expression by mTORC1 and c-Myc.
To further assess the relationship between c-Myc and
mTORC1 in the regulation of transcription, we examined the
distribution of E-boxes among rapamycin responsive genes in the
WB-F344 and WB311 hepatic cells. The significance of E-boxes
lies in their role in c-Myc function in that c-Myc regulation of
target genes appears to involve direct binding to E-boxes.
Mutations in the E-boxes of two c-Myc target genes, nucleolin
and BN51, result in the abrogation of transcriptional activation by
c-Myc [36]. Mutations in E-boxes are also associated with the
removal of the repression of gene activation induced by the c-Myc
binding partner Mad [36]. Further, recent studies have shown that
upregulated c-Myc targets in the HOMycER12 fibroblasts
induced by OHT were enriched for E-boxes (manuscript in
preparation, Sedivy et al.). We found that the E-box distribution
along the promoter region of rapamycin-regulated genes in the
WB-F344 and WB311 cells was similar and that they resembled
the distribution observed in drosophila [37] and humans [25]. The
Figure 5. Enrichment of c-Myc targets among rapamycin
targets in rat fibroblasts. TGR-1 cells (c-myc
+/+; Upper Panel) and c-
HO15.19 cells (c-myc
2/2; Lower Panel) were treated with rapamycin
(50 nM) for 24 hr. At the end of that time, cells were processed for the
preparation of RNA, which was used for microarray analysis. The genes
affected by rapamycin were compared to c-Myc targets that were
identified as genes whose expression was altered in response to c-Myc
induction by OHT in HOMycER12 fibroblasts. The expected (unfilled),
observed (black), upregulated (red) and downregulated (green) c-Myc
targets regulated in response to rapamycin are shown for the temporal
response clusters 1, 2 and 3 in the HOMycER12 fibroblasts and for the
total population of genes affected in these cells. *, P,0.05 versus
corresponding control were determined by chi square analysis.
doi:10.1371/journal.pone.0009084.g005
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TGR-1
Pathway *
{ P Value
{ Genes (Total)
1 Genes (Significant)
I
Adipocytokine signaling pathway . 0.001 58 9
Alanine and aspartate metabolism . 0.003 22 5
Aminoacyl-tRNA biosynthesis . 3.52E-06 28 9
B cell receptor signaling pathway . 0.037 52 6
Bile acid biosynthesis . 0.027 14 3
Biosynthesis of steroids . 2.27E-07 16 8
Biosynthesis of unsaturated fatty acids . 0.039 16 3
Carbon fixation . 0.006 16 4
Chronic myeloid leukemia . 0.004 66 9
Colorectal cancer . 0.026 61 7
Complement and coagulation cascades . 0.043 54 6
Fructose and mannose metabolism . 0.0006 23 6
Glioma . 0.026 48 6
Glycine, serine and threonine metabolism . 9.53E-05 32 8
Glycolysis/Gluconeogenesis . 0.0009 34 7
Neuroactive ligand-receptor interaction m 0.004 211 2
Non-small cell lung cancer . 0.014 42 6
Olfactory transduction m 2.87E-15 687 1
Pancreatic cancer . 0.028 62 7
Pentose phosphate pathway . 0.033 15 3
Phenylalanine metabolism . 0.022 13 3
Phenylalanine, tyrosine and tryptophan biosynthesis . 0.00016 7 4
Prostate cancer . 0.019 71 8
Proteasome . 0.00025 20 6
Small cell lung cancer . 0.012 65 8
Terpenoid biosynthesis . 0.013 4 2
TGF-beta signaling pathway . 0.04 67 7
Thyroid cancer . 0.004 23 5
Urea cycle and metabolism of amino groups . 0.0076 17 4
Valine, leucine and isoleucine degradation . 0.0009 25 6
HO15.19
Pathway P Value Genes (Total) Genes (Significant)
Alanine and aspartate metabolism . 0.0044 22 5
Alzheimer’s disease . 0.037 25 4
Aminoacyl-tRNA biosynthesis . 4.98E-08 28 11
Bile acid biosynthesis . 0.032 14 3
Biosynthesis of steroids . 0.0076 16 4
Bisphenol A degradation . 0.015 4 2
Carbon fixation . 0.046 16 3
Cell cycle . 0.0017 89 12
DNA replication . 9.31E-05 30 8
ECM-receptor interaction . 0.0098 59 8
Focal adhesion . 0.018 142 14
Fructose and mannose metabolism . 0.0054 23 5
Glycine, serine and threonine metabolism . 0.001 32 7
Glycolysis/Gluconeogenesis . 0.028 34 5
MAPK signaling pathway . 0.0044 201 20
Mismatch repair . 0.0095 17 4
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the transcription start site. We found that the majority of
promoters in rapamycin-regulated genes in the WB-F344 and
WB311 cells contained one E-box. We did not find a difference in
the number or distribution of E-boxes among genes that were
upregulated versus downregulated in response to rapamycin. In
summary, our data indicate that c-Myc and mTORC1 may
overlap in their regulation of transcription via E-boxes, but that
this overlap is independent of c-Myc itself.
Although c-Myc and mTOR are known to be central regulators
of comparable biological processes, this is the first study, to our
knowledge, that has identified a set of genes that are targets of both
c-Myc and mTORC1. mTOR [13,38] and c-Myc [38] are known
to regulate cellular metabolism and, more specifically, glucose
metabolism [38,39]. We found that rapamycin affected various
metabolic and biosynthetic pathways in the TGR-1 and HO15.19
cells, similar to our observations in the WB-F344 and WB311 cells.
The glycolysis/gluconeogenesis pathway was affected by rapamy-
cin in all four cell lines with the gene for phosphoglycerate kinase-1
(Pgk1) being downregulated in every case. Further study would be
warranted to determine the significance of this observation.
With regard to the intersection between c-Myc and mTOR
signaling, our pathway network reconstruction analyses indicated a
role for c-myc in mTORC1 action in the WB-F344, WB311 and
TGR-1 cell lines. Prior studies have shown that rapamycin can
downregulate both the transcription [40] and translation [40–42] of
c-myc in several cell types. It may be that the effect of rapamycin on
the expression of c-myc and cyclin D is not uniform and is cell type
specific. Other studies examining the intersection between c-Myc
and mTOR have demonstrated an ability of c-Myc to modulate
signaling through the mTOR pathway via transcriptional downreg-
ulation of the tuberous sclerosis complex genes [43,44], which are
negative regulators of mTOR-mediated translation activation.
Finally, c-Myc has been shown to abrogate the regulation of
translation by mTOR by controlling the expression and activity of
the key translation regulator, 4EBP-1 [45].
In summary, we have demonstrated an intersection between
mTORC1 and c-Myc regulation of gene expression. This was
observed in both hepatic cells and fibroblasts. However, control of
gene expression by mTORC1 was independent of c-Myc,
indicating that the intersection between these two systems is likely
a reflection of their biological function, not their mechanism of
gene expression control. Furthermore, our inability to detect the
involvement of specific transcription factor binding domains in the
regulation of gene expression by mTORC1 may indicate the
involvement of epigenetic mechanisms, microRNAs or both in
mTORC1 signaling.
Supporting Information
Table S1 Identification of genes that are regulated in both
the WB-F344 and WB311 cells in response to rapamycin. The
X to the left of a row indicates that the gene is one that was co-
regulated in the two cell lines and one for which an Ensembl
ID allowed further analysis in Toucan2. Arrowheads indicate
the direction of the effect of rapamycin (increase or decrease
in expression following exposure to rapamycin). The magni-
tude of rapamycin effect is given as log-base 2 of the fold-
change.
Found at: doi:10.1371/journal.pone.0009084.s001 (0.25 MB
DOC)
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HO15.19
Pathway P Value Genes (Total) Genes (Significant)
Neuroactive ligand-receptor interaction m 0.0019 211 2
Notch signaling pathway . 0.014 39 6
Nucleotide excision repair . 0.0091 36 6
Olfactory transduction m 5.35E-18 687 0
p53 signaling pathway . 0.013 50 7
Prion disease . 0.012 10 3
Purine metabolism . 0.0047 100 12
Pyrimidine metabolism . 1.51E-05 55 12
Renal cell carcinoma . 0.013 50 7
Ribosome . 0.018 53 7
Tyrosine metabolism . 0.037 25 4
Valine, leucine and isoleucine biosynthesis . 0.004 7 3
Valine, leucine and isoleucine degradation . 0.008 25 5
* Pathways that were affected by rapamycin in both cell lines are shown in bold italic font.
{ The downward and upward pointing arrowheads indicate whether pathways were down- or up-regulated, respectively, in response to rapamycin.
{ Corrected P-values were calculated using the Fisher exact test.
1 Genes (total), number of genes associated with a given pathway.
I Significant genes, number of genes associated with a given pathway that were significantly affected by rapamycin.
doi:10.1371/journal.pone.0009084.t003
Table 3. Cont.
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